NO20053018L - Pyrazoloquinoliner med immunmodulerende aktivitet. - Google Patents

Pyrazoloquinoliner med immunmodulerende aktivitet.

Info

Publication number
NO20053018L
NO20053018L NO20053018A NO20053018A NO20053018L NO 20053018 L NO20053018 L NO 20053018L NO 20053018 A NO20053018 A NO 20053018A NO 20053018 A NO20053018 A NO 20053018A NO 20053018 L NO20053018 L NO 20053018L
Authority
NO
Norway
Prior art keywords
pyrazoloquinolines
methods
immunomodulatory activity
heterocyclic compounds
relates
Prior art date
Application number
NO20053018A
Other languages
English (en)
Other versions
NO20053018D0 (no
Inventor
Lars Olof Goran Pettersson
Ian Richard Matthews
Thomas Stephen Coulter
Chiara Ghiron
Chris James Brennan
Muhammed Kamal Uddin
Dorthe Da Graca Thrige
Philip Huxley
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203471A external-priority patent/SE0203471D0/xx
Priority claimed from SE0301299A external-priority patent/SE0301299D0/xx
Priority claimed from SE0301851A external-priority patent/SE0301851D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of NO20053018D0 publication Critical patent/NO20053018D0/no
Publication of NO20053018L publication Critical patent/NO20053018L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet nye heterocykliske forbindelser, fremgangsmåter for deres fremstilling, sammensetninger som inneholde disse samt fremgangsmåter og anvendelse for klinisk behandling av medisinske tilstander som kan begunstiges ved immunomodulering innbefattende rheumatoid artritt, multippel sklerose, diabetes, astma, transplantasjon, systemisk lupus erytematosis og psoriasis. Mer spesielt er det beskrevet nye heterocykliske forbindelser som er CD80-antagonister som er i stand til å inhibere interaksjonen mellom CD80 og CD28.
NO20053018A 2002-11-22 2005-06-20 Pyrazoloquinoliner med immunmodulerende aktivitet. NO20053018L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US42824002P 2002-11-22 2002-11-22
SE0203471A SE0203471D0 (sv) 2002-11-22 2002-11-22 Immunomodulatory compunds
SE0301299A SE0301299D0 (sv) 2003-05-06 2003-05-06 Immunomodulatory compounds
US48212203P 2003-06-25 2003-06-25
SE0301851A SE0301851D0 (sv) 2003-06-25 2003-06-25 Immunomodulatory compounds
PCT/SE2003/001805 WO2004048378A1 (en) 2002-11-22 2003-11-21 Pyrazoloquinolines with immunomodulating activity

Publications (2)

Publication Number Publication Date
NO20053018D0 NO20053018D0 (no) 2005-06-20
NO20053018L true NO20053018L (no) 2005-08-22

Family

ID=32398347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053018A NO20053018L (no) 2002-11-22 2005-06-20 Pyrazoloquinoliner med immunmodulerende aktivitet.

Country Status (14)

Country Link
US (2) US7081456B2 (no)
EP (2) EP1813616B1 (no)
JP (1) JP2006509047A (no)
CN (1) CN100347173C (no)
AT (1) ATE353898T1 (no)
AU (1) AU2003279687A1 (no)
CA (1) CA2506524A1 (no)
DE (1) DE60311861T2 (no)
ES (1) ES2282693T3 (no)
HK (1) HK1086562A1 (no)
NO (1) NO20053018L (no)
NZ (1) NZ540081A (no)
RU (1) RU2328496C2 (no)
WO (1) WO2004048378A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60326639D1 (de) * 2002-12-16 2009-04-23 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
CA2519063C (en) 2003-03-14 2011-05-10 Avidex Limited Immunomodulating heterocyclic compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
AU2004322237B2 (en) 2004-08-09 2011-09-22 Medigene Ag Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
WO2008043072A2 (en) * 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
EP2676666A1 (en) * 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
CN102977095B (zh) * 2012-12-03 2015-10-28 华东理工大学 吡唑并喹啉类化合物及其用途
US9809589B2 (en) * 2012-12-22 2017-11-07 Kbp Biosciences Co., Ltd. Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
CN110698456B (zh) * 2019-11-06 2021-05-14 重庆医药高等专科学校 一种2,3-二氢硫代色烯-4-酮及其衍生物的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) * 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4312870A (en) * 1979-06-21 1982-01-26 Ciba-Geigy Corporation Pyrazoloquinolines
PH21213A (en) * 1984-10-26 1987-08-21 Fujisawa Pharmaceutical Co Benzene- and pyrazole- fused heterocyclic compound and pharmaceutical composition comprising the same
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
JPH05505180A (ja) * 1990-02-02 1993-08-05 ザ ブーツ カンパニー ピーエルシー 治療薬
GB9002423D0 (en) * 1990-02-06 1990-04-04 Boots Co Plc Therapeutic agents
CN1069272A (zh) * 1991-08-02 1993-02-24 布茨公司 制备苯并吡或噻喃并吡唑的方法
AR006520A1 (es) * 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
US6642249B2 (en) * 2001-07-04 2003-11-04 Active Biotech Ab Immunomodulating compounds
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds

Also Published As

Publication number Publication date
CN1729191A (zh) 2006-02-01
CA2506524A1 (en) 2004-06-10
RU2328496C2 (ru) 2008-07-10
JP2006509047A (ja) 2006-03-16
EP1813616A3 (en) 2007-08-08
US20060217411A1 (en) 2006-09-28
US20040116461A1 (en) 2004-06-17
ATE353898T1 (de) 2007-03-15
RU2005119639A (ru) 2006-01-20
AU2003279687A1 (en) 2004-06-18
WO2004048378A1 (en) 2004-06-10
US7291612B2 (en) 2007-11-06
EP1813616A2 (en) 2007-08-01
EP1562944B1 (en) 2007-02-14
DE60311861T2 (de) 2007-11-22
DE60311861D1 (de) 2007-03-29
CN100347173C (zh) 2007-11-07
US20050203118A9 (en) 2005-09-15
ES2282693T3 (es) 2007-10-16
NZ540081A (en) 2008-03-28
NO20053018D0 (no) 2005-06-20
HK1086562A1 (en) 2006-09-22
EP1813616B1 (en) 2013-03-27
US7081456B2 (en) 2006-07-25
EP1562944A1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
NO20053018D0 (no) Pyrazoloquinoliner med immunmodulerende aktivitet.
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
WO2012080284A3 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
MXPA06011194A (es) Tiadiazolidinonas como inhibidores de gsk-3.
HUP0303164A2 (hu) Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
WO2009025839A3 (en) Phosphodiesterase 10 inhibitors
NO20035684D0 (no) Immunomodulerende forbindelser
PE20061080A1 (es) Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
ATE425164T1 (de) Tetrazyklische immunmodulierende verbindungen
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
NO20032291L (no) Pyrimidinderivater
DE602004029383D1 (de) Isten und antagonisten
NO20080285L (no) Alfa-(aryl- eller heteroarylmetyl)-beta-piperidinopropionsyreforbindelser som ORL-1-reseptorantagonist
NO20053562L (no) Nye aminobenzofenonforbindelser
HUP0500082A2 (hu) Endotelin-antagonista aktivitású alkán-szulfonamidok és alkalmazásuk
WO2005025492A3 (en) Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease
NO20076676L (no) Nye 8-sulfonyl-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptor
WO2012059443A3 (en) Novel neurotrypsin inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application